Advanced Perfusion Diagnostics
APD developed a single-use device for non-invasive and continuous assessment of microcirculation in critical care and surgical settings. The APD product will detect early signs of sepsis hours, if not days, before the tests currently used and the clinical symptoms. It is based on subtle changes in urethral perfusion. Impairment of local microcirculation during septic shock is a triggering factor for multi-organ dysfunction syndrome and subsequent death. Despite its therapeutic importance, assessment of microcirculation remains difficult, with only non-continuous and deferred measurements when available. After going through pre-clinical validation, First-in-Man clinical trials and receiving CE mark in 2016 for an initial version of the product, APD was acquired by Vygon in 2019.
Sector
Medical Devices
Strategy
Status
Exit
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.